Form 4: Bioxytran Director Dale H. Conaway Acquires 70,423 Shares of Common Stock
SEC Form 4 Filing
Director Dale H. Conaway reports the acquisition of 70,423 shares of Bioxytran, Inc. common stock at a price of $0.142 per share on April 19, 2024.
Summary
- On April 19, 2024, Dale H. Conaway, a director of Bioxytran, Inc., acquired 70,423 shares of common stock.
- The purchase price was $0.142 per share.
- Following the transaction, Conaway directly owns 936,122 shares of Bioxytran, Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It reflects a routine transaction by a company director. The purchase could be interpreted as a positive signal, but without additional context, it's difficult to gauge the overall impact.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure required by the SEC for corporate insiders and provides transparency into their trading activities.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment, as insider buying is often viewed favorably.
Key Dates
| Date | Description |
|---|---|
| 04/19/2024 | Date of transaction: Dale H. Conaway acquired 70,423 shares of Bioxytran, Inc. common stock. |
Keywords
Bioxytran, Director, Stock Acquisition, Form 4, BIXT, Common Stock, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.